4//SEC Filing
Sandrock Alfred 4
Accession 0001104659-25-016520
CIK 0001640266other
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 4:20 PM ET
Size
10.6 KB
Accession
0001104659-25-016520
Insider Transaction Report
Form 4
Sandrock Alfred
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2025-02-21+290,000→ 290,000 totalExercise: $4.22Exp: 2035-02-21→ Common Stock (290,000 underlying) - Sale
Common Stock
2025-02-20$4.24/sh−11,702$49,616→ 296,816 total - Award
Common Stock
2025-02-21+145,000→ 441,816 total
Footnotes (4)
- [F1]Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2025. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.32, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Consists of shares of common stock issuable under an aggregate of 145,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
- [F4]This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.
Documents
Issuer
Voyager Therapeutics, Inc.
CIK 0001640266
Entity typeother
Related Parties
1- filerCIK 0001577061
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 4:20 PM ET
- Size
- 10.6 KB